natgillin/translations-raw huggingface dataset:
Aesica Queenborough Limited, Queenborough, Kent ME11 5EL, United Kingdom AbbVie Logistics B.V., Zuiderzeelaan 53, 8017 JV Zwolle, The Netherlands
Aesica Queenborough Limited, Queenborough, Kent ME11 5EL, Velika Britanija AbbVie Logistics B.V., Zuiderzeelaan 53, 8017 JV Zwolle, Nizozemska
Aesica Queenborough Ltd, Queenborough, Kent ME11 5EL, United Kingdom AbbVie Logistics B.V., Zuiderzeelaan 53, 8017 JV Zwolle, The Netherlands
Aesica Queenborough Ltd, Queenborough, Kent ME11 5EL, Velika Britanija AbbVie Logistics B.V., Zuiderzeelaan 53, 8017 JV Zwolle, Nizozemska
AESIs will be defined as follows:
Kot posebej zanimivi neželeni učinki bodo opredeljeni:
AESIs will be defined as follows:
Neželeni učinki posebnega interesa so opredeljeni, kot sledi:
AF03 adjuvant composed of squalene (33 mg), sorbitan oleate (4.9 mg), polyoxyethylene cetostearyl ether (6.3 mg), mannitol (6.1 mg) per 1 ml
Adjuvans (AF03), ki ga sestavljajo skvalen (33 miligramov), sorbitan oleat (4,9 miligramov), makrogol cetil stearileter (6,3 miligramov), manitol (6,1 miligramov) na 1 ml.
Afamelanotide has moderate influence on the ability to drive and use machines, especially within 72 hours of administration.
Afamelanotid ima zmeren vpliv na sposobnost vožnje in upravljanja s stroji, predvsem v 72 urah po vsaditvi.
Afamelanotide is thought to mimic the endogenous compound’s pharmacological activity by activating the synthesis of eumelanin mediated by the MC1R receptor.
Domneva se, da afamelanotid posnema farmakološko delovanje endogene sestavine, tako da aktivira sintezo evmelanina, v katero je vključen receptor MC1R.
Afamelanotide works in a way similar to the natural hormone, by making skin cells produce eumelanin which is a brown-black type of melanin pigment in the body.
Afamelanotid deluje na podoben način kot naravni hormon, tako da v kožnih celicah spodbuja tvorbo evmelanina, ki je rjavo-črni melaninski pigment v telesu.
Afatinib 20 mg, single dose
Odmerek Odmerek
Afatinib retains significant anti-tumour activity in NSCLC cell lines in vitro and/or tumour models in vivo (xenografts or transgenic models) driven by mutant EGFR isoforms known to be resistant to the reversible EGFR inhibitors erlotinib and gefitinib such as T790M or T854A.
Afatinib ohrani pomembno protitumorsko aktivnost pri celičnih linijah NSCLC in vitro in/ali tumorskih modelih in vivo (ksenografski ali transgenski modeli) z mutiranimi izoformami EGFR, za katere je znano, da so odporne proti reverzibilnima zaviralcema EGFR erlotinibu in gefitinibu, kot sta T790M ali T854A.
Afebrile convulsions or seizures, Bell’s palsy, Cerebrovascular accident, Dizziness, Dream abnormality, Encephalitis*, Encephalopathy*, Guillain-Barré syndrome, Measles inclusion body encephalitis (see section 4.3), Ocular palsies, Paraesthesia, Polyneuritis, Polyneuropathy, Subacute sclerosing panencephalitis*, Syncope, Transverse myelitis, Tremor
nevročinski krči ali napadi, Bellova pareza, možganskožilni dogodek, omotica, nenormalne sanje, encefalitis*, encefalopatija*, Guillain-Barréjev sindrom, ošpični encefalitis z inkluzijskimi telesci (glejte poglavje 4.3), očesne paralize, parestezija, polinevritis, polinevropatija, subakutni sklerozirajoči panencefalitis*, sinkopa, transverzni mielitis, tremor
afety needle pre-filled syringes (5 ml each) 2 safety needles
1 varnostna igla 2 napolnjeni injekcijski brizgi (5 ml) 2 varnostni igli
afety when
lovastatin
afety when
ritonavir1
afety, have not been
(formulacija s trdim gelom))
Affect lability
čustvena labilnost
Affect lability Anxiety Insomnia Psychotic disorder
čustvena labilnost anksioznost nespečnost psihotične motnje
Affect lability Apathy Dysphoria Sleep disorder Bruxism
disforija motnje spanja bruksizem zmanjšan libido
Affect lability, aggression, confusional state, euphoric mood, hallucination, mania, paranoia, psychosis†, suicide attempt, suicide ideation*
čustvena labilnost, nasilno vedenje, zmedenost, evforično razpoloženje, halucinacije, manija, paranoja, psihoza†, poskus samomora, misli na samomor
affect lability, aggression, confusional state, euphoric mood, hallucination, mania, paranoia, psychosis†, suicide attempt, suicide ideation*
čustvena labilnost, nasilno vedenje, zmedenost, evforično razpoloženje, halucinacije, manija, paranoja, psihoza‡, poskus samomora, misli na samomor
affect lability, aggression, confusional state, euphoric mood, hallucination, mania, paranoia, psychosis‡, suicide attempt, suicide ideation
čustvena labilnost, nasilno vedenje, zmedenost, evforično razpoloženje, halucinacije, manija, paranoja, psihoza‡, poskus samomora, misli na samomor
Affect lability, agitation, libido disorder, mood altered, sleep disorder
čustvena labilnost, agitacija, motnja libida, spremembe razpoloženja, motnje spanja
Affected pigs often have a cough and fail to thrive.
Okuženi prašiči imajo pogosto kašelj in se ne razvijajo.
Affecting other parts of the body difficulty breathing / wheezing, symptoms of allergic reaction (swelling, redness of the eye and rash of the skin), changes in your taste sensation, slowing of heart rate, difficulty sleeping, nightmare, asthma, hair loss, tiredness.
Učinki na druge dele telesa težave pri dihanju/sopihanje, simptomi alergijske reakcije (otekanje, pordelost oči in izpuščaj na koži), spremembe v občutenju okusa, upočasnitev srčnega utripa, težave s spanjem, nočne more, astma, izpadanje dlak, utrujenost.
Affecting other parts of the body headache, darker skin colour around the eye.
Učinki na druge dele telesa glavobol, temnejša koža okrog očesa.
Affecting other parts of the body runny nose, hair growing around the eye, dizziness, headache.
Učinki na druge dele telesa nahod, poraščenost okrog oči, omotica, glavobol
Affecting other parts of the body slowing of heart rate, symptoms of allergic reaction (swelling, redness of the eye and rash of the skin), asthma, shortness of breath.
Učinki na druge dele telesa upočasnjevanje srčnega utripa, simptomi alergijske reakcije (otekanje, pordelost oči in izpuščaj na koži), astma, težko dihanje.
Affecting other parts of the body tiredness.
Učinki na druge dele telesa utrujenost.
affecting the benefit-risk balance of the vaccine.
razmerje koristi in tveganj cepiva.
Affecting the eye eye swelling
Učinki na oko otekanje oči.
affects 1 to 10 users in 1,000
pojavijo se pri 1 do 10 od 1.000 bolnikov
affects 1 to 10 users in 1,000
prizadene 1 do 10 od 1.000 bolnikov
affects 1 to 10 users in 10,000
pojavijo se pri 1 do 10 od 10.000 bolnikov
affects 1 to 10 users in 10,000
prizadene 1 do 10 od 10.000 bolnikov
affects 1 to 10 users in 10,000
prizadene manj kot 1 od 10.000 bolnikov
affects 1 to 10 users in 100
pojavijo se pri 1 do 10 od 100 bolnikov
affects 1 to 10 users in 100
prizadene 1 do 10 od 100 bolnikov
affects less than 1 user in 10,000
pojavijo se pri manj kot 1 od 10.000 bolnikov
affects more than 1 user in 10
pojavijo se pri več kot 1 od 10 bolnikov
Afinitor 2.5 mg is available in packs containing 30 or 90 tablets.
Zdravilo Afinitor 2,5 mg je na voljo v pakiranjih, ki vsebujejo 30 ali 90 tablet.
Afinitor 2.5 mg tablets are white to slightly yellowish, elongated tablets.
Tablete Afinitor 2,5 mg so podolgovate tablete, bele do nekoliko rumenkaste barve.
Afinitor 5 mg and Afinitor 10 mg are available in packs containing 10, 30 or 90 tablets.
Zdravili Afinitor 5 mg in Afinitor 10 mg sta na voljo v pakiranjih, ki vsebujejo 10, 30 ali 90 tablet.
Afinitor could harm a breast-fed baby.
Zdravilo Afinitor lahko škoduje dojenemu otroku.
Afinitor could harm an unborn baby and is not recommended during pregnancy.
Zdravilo Afinitor lahko škoduje nerojenemu otroku in med nosečnostjo ni priporočeno.
Afinitor is a medicine that contains the active substance everolimus.
Afinitor je zdravilo, ki vsebuje zdravilno učinkovino everolimus.
Afinitor is indicated for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.
Zdravilo Afinitor je indicirano za zdravljenje na hormonske receptorje pozitivnega in HER2/neu negativnega napredovalega raka dojke, in sicer v kombinaciji z eksemestanom pri ženskah v pomenopavzi, pri katerih ne gre za simptomatsko prizadetost visceralnih organov ob ponovitvi oziroma napredovanju bolezni po zdravljenju z nesteroidnim zaviralcem aromataze.
Afinitor is indicated for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease (see sections 4.4 and 5.1).
Zdravilo Afinitor je indicirano za zdravljenje neresektabilnih ali metastatskih, dobro diferenciranih (gradus 1 ali gradus 2), nefunkcionalnih nevroendokrinih tumorjev gastrointestinalnega ali pljučnega izvora pri odraslih z napredovalo boleznijo (glejte poglavji 4.4 in 5.1).
Afinitor is not to be used in children or adolescents (age below 18 years).
Zdravilo Afinitor ni namenjeno uporabi pri otrocih in mladostnikih (starih manj kot 18 let).
Afinitor is used in breast cancer that is ‘hormone receptor-positive’ (when the cancer cells have oestrogen receptors on their surface) and ‘HER2/neu negative’ (when the cancer cells do not contain high levels of the HER2/neu [human epidermal growth factor receptor-2] protein).
Zdravilo Afinitor se uporablja pri zdravljenju raka dojke, pozitivnega na hormonske receptorje (kadar imajo rakave celice na površini receptorje za estrogen) in negativnega na HER2/neu (ko rakave celice ne vsebujejo visokih ravni beljakovine HER2/neu [receptorja-2 za humani epidermalni rastni dejavnik]).
Afinitor is used to treat the following cancers:
Zdravilo Afinitor se uporablja za zdravljenje naslednjih vrst raka:
Afinitor may affect male fertility.
Zdravilo Afinitor lahko vpliva na plodnost pri moških.
Afinitor may elevate cholesterol and/or other blood fats. if you have had recent major surgery, or if you still have an unhealed wound following surgery.
Zdravilo Afinitor lahko zviša raven holesterola in/ali drugih maščob v krvi. če ste imeli nedavno večjo operacijo ali imate še vedno nezaceljeno rano po operaciji.
Afinitor may increase the risk of problems with wound healing. if you have an infection.
Zdravilo Afinitor lahko poveča tveganje za težave pri celjenju rane. če imate okužbo.
Afinitor was more effective than placebo at treating patients in all studies.
Zdravilo Afinitor je bilo v vseh študijah učinkovitejše od placeba.
Afinitor was superior to placebo for the primary endpoint of progression-free survival, with a statistically significant 67% reduction in the risk of progression or death (see Table 7 and Figure 5).
Zdravilo Afinitor je bilo boljše od placeba glede primarnega cilja opazovanja, to je preživetja brez napredovanja bolezni, in sicer s statistično značilnim 67-odstotnim zmanjšanjem tveganja za napredovanje bolezni ali smrt (glejte preglednico 7 in sliko 5).
Afinitor with food and drink
Zdravilo Afinitor skupaj s hrano in pijačo
Aflibercept acts as a soluble decoy receptor that binds to VEGF-A, with higher affinity than its native receptors, as well as the related ligands PlGF and VEGF-B.
Aflibercept deluje kot topni slepilni receptor (decoy receptor), ki se veže na VEGF-A z večjo afiniteto kot njegovi nativni receptorji in sorodna liganda PlGF in VEGF-B.
Aflibercept administration should be suspended for ≥2 grams of proteinuria/24 hours and restarted when proteinuria is <2 grams/24 hours.
Uporabo aflibercepta je treba prekiniti, če je proteinurija ≥ 2 grama na 24 ur, in jo znova začeti, ko se zmanjša na < 2 grama na 24 ur.
Aflibercept has been shown to be embryotoxic and teratogenic when administered intravenously to pregnant rabbits every 3 days during the organogenesis period (gestation days 6 to 18) at doses approximately 1 to 15 times the human dose of 4 mg/kg every 2 weeks.
Aflibercept se je izkazal za embriotoksičnega in teratogenega, če je bil pri brejih kunkah med obdobjem organogeneze (od 6. do 18. dne gestacije) vsak 3 dan uporabljen intravensko v odmerkih, ki so bili približno od 1- do 15-krat tolikšni, kot je odmerek za človeka 4 mg/kg vsaka 2 tedna.
Aflibercept impaired wound healing in animal models (see section 5.3).
Aflibercept je v živalskih modelih poslabšal celjenje ran (glejte poglavje 5.3).
Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of
Aflibercept je dimeren glikoprotein z beljakovinsko molekulsko maso 97 kilodaltonov (kDa) in vsebuje glikozilate, ki pomenijo dodatnih 15 % celotne molekulske mase, tako da je skupna molekulska masa 115 kDa.
Aflibercept should be discontinued in patients that develop PRES (see section 4.2).
Če se pojavi PRES, je treba zdravljenje z afliberceptom prekiniti (glejte poglavje 4.2).
Aflibercept treatment should be discontinued in patients who experience an ATE (see section 4.2).
Pri bolnikih, ki se jim pojavi arterijski trombembolični dogodek, je treba zdravljenje z afliberceptom prekiniti (glejte poglavje 4.2).
Aflibercept, the active substance in Eylea, blocks the activity of a group of factors, known as Vascular Endothelial Growth Factor A (VEGF-A) and Placental Growth Factor (PlGF).
Aflibercept, zdravilna učinkovina v zdravilu Eylea, zavira delovanje skupine dejavnikov, znanih kot VEGF-A (žilni endotelijski rastni dejavnik A) in PlGF (placentni rastni dejavnik).
Aflunov contains a flu strain called A/turkey/Turkey/1/05 (H5N1)-like strain (NIBRG-23).
Cepivo Aflunov vsebuje sev virusa gripe, imenovan sevu A/turkey/Turkey/1/05 (H5N1) podoben sev (NIBRG-23).
Aflunov is a vaccine that contains parts of influenza (flu) viruses that have been inactivated.
Zdravilo Aflunov je cepivo, ki vsebuje dele virusov gripe, ki so bili inaktivirani.
Aflunov is a ‘prepandemic’ vaccine.
Zdravilo Aflunov je „prepandemično“ cepivo.
Aflunov is used in adults to protect against flu caused by the H5N1 (‘bird flu’) strain of the influenza A virus.
Cepivo Aflunov se uporablja pri odraslih za zaščito proti gripi, ki jo povzroča sev H5N1 virusa gripe A („ptičja gripa“).
Aflunov prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
Aflunov prepandemično cepivo proti gripi (H5N1) (s površinskimi antigeni, inaktivirano, z adjuvansom)
Aflunov should not be given to patients who have had an anaphylactic reaction (severe allergic reaction) to any of the components of the vaccine, including those found at trace (very low levels) such as egg or chicken protein, ovalbumin (a protein in egg white), kanamycin or neomycin sulphate (antibiotics), barium sulphate, formaldehyde and cetyltrimethylammonium bromide.
Cepiva Aflunov ne smejo prejeti bolniki, ki so kdaj imeli anafilaktično reakcijo (hudo alergijsko reakcijo) na katero koli sestavino cepiva, vključno s katero koli snovjo, ki je v cepivu prisotna v sledeh (zelo majhnih količinah), kot so jajčne ali kokošje beljakovine, ovalbumin (beljakovina v jajčnem beljaku), kanamicin ali neomicinsulfat (antibiotika), barijev sulfat, formaldehid in cetiltrimetilamonijev bromid.
AFLUNOV, containing HA from A/Vietnam/1194/2004 (homologous to the challenge strain) and an AFLUNOV-like H5N1 vaccine, containing hemagglutinin from the A/turkey/Turkey/1/2005-like (heterologous to the challenge strain) were tested.
z A/Vietnam/1194/2004 (homológna na stimulujúci kmeň) a vakcína podobná vakcíne AFLUNOV H5N1, obsahujúca hemaglutinín z variantu kmeňa A/turkey/Turkey/½005 (heterológny na stimulujúci kmeň).
afoxolaner / milbemycin oxime Tablets
afoxolaner/milbemicyn oxime tablete
Afoxolaner acts as an antagonist at ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA).
Afoksolaner deluje na od ligandov odvisne klorove kanalčke, predvsem tiste ki so pod vplivom nevrotransmiterja gamaaminobutirične kisline (GABA).
Afoxolaner acts at ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA), thereby blocking pre- and post-synaptic transfer of chloride ions across cell membranes.
Afoksolaner deluje na od ligandov odvisne klorove kanalčke, predvsem tiste ki so pod vplivom nevrotransmiterja gamaaminobutirične kisline (GABA), s čimer zavirajo pre- in post-sinaptični prehod kloridnih ionov skozi celično membrano.
Afoxolaner had high systemic absorption.
Afoksolaner ima visoko sistemsko absorbcijo.
Afoxolaner in the dog is metabolized to more hydrophilic compounds and then eliminated.
Afoksolaner se pri psih metabolizira v bolj hidrofilne komponente in se nato izloči.
Afoxolaner is an insecticide and acaricide belonging to the isoxazoline family.
Afoksolaner je insekticid in akaricid in skupine isoksazolinov.
Afoxolaner is an insecticide and acaricide of the isoxazoline family.
Afoksolaner je insekticid in akaricid in skupine isoksazolinov.
Afoxolaner kills fleas and ticks that have ingested the dog’s blood by acting on their nervous system.
Afoksolaner ubije bolhe in klope, ki so zaužile kri psa, tako da deluje na njihov živčni sistem.
Afoxolaner kills fleas before egg production and therefore prevents the risk of household contamination.
Zdravilo ubije bolhe preden lahko izležejo jajčeca, zato preprečuje kontaminacijo okolice za razvojnimi oblikami bolh.
Afoxolaner kills fleas before they can lay eggs and so helps to reduce contamination of the dogs’ environment.
Afoksolaner ubije bolhe, preden izležejo jajčeca, s čimer pomaga zmanjšati kontaminacijo okolice psa.
Afoxolaner kills fleas before they can lay eggs and so helps to reduce contamination of the dogs’ environment.
Afoksolaner uniči bolhe, preden te lahko izležejo jajčeca, in tako pomaga zmanjšati kontaminacijo okolja psa.
African-America/African Heritage/Other
afroameričani/afriški staroselci/ostali
African-American patients
Bolniki afroameriškega porekla
African-American/African Heritage/Other
Afro-Američani/Afričani Staroselci/drugo
After
Po zaključenem
After 1 or 2 doses of 106.7 TCID50 vaccine, haemagglutination inhibition (HAI) and IgA seroresponses were each detected in 10% subjects, and nasal wash IgA responses were detected in 24% subjects.
Po 1 ali 2 odmerkih 106,7 TCID50 cepiva so vsakega od seroloških odzivov (inhibicijo hemaglutinacije [HAI] in IgA odziv) ugotovili pri 10 % preiskovancev, IgA odziv v nosnem izpirku pa pri 24 % preiskovancev.
After 1 or 2 doses of 107.5 TCID50 vaccine, HAI and IgA seroresponses were each detected in 10% and 52% of subjects and nasal IgA responses were detected in 19% of subjects.
Po 1 ali 2 odmerkih 107,5 TCID50 cepiva so serološka odziva HAI in IgA ugotovili pri 10 % in 52 % preiskovancev, IgA odziv v nosnem izpirku pa pri 19 % preiskovancev.
After 1 year of treatment, around 66% of patients receiving Imbruvica were still alive with their disease not having progressed compared with around 6% of patients receiving ofatumumab.
Po enoletnem zdravljenju je bilo približno 66 % bolnikov, ki so prejemali zdravilo Imbruvica, še živih in brez napredovanja bolezni v primerjavi s približno 6 % bolnikov, ki so prejemali ofatumumab.
After 1-hour intravenous administration at 25 mg/m2 cabazitaxel in patients with metastatic prostate cancer (n=67), the Cmax was 226 ng/ml (Coefficient of Variation (CV): 107%) and was reached at the end of the 1-hour infusion (Tmax).
Po 1-urni intravenski uporabi 25 mg/m2 kabazitaksela pri bolnikih z metastatskim rakom prostate (n = 67) je bila Cmax 226 ng/ml (koeficient variacije (KV): 107 %) in je bila dosežena na koncu 1-urnega infundiranja (tmax).
After 10 seconds pull the pen straight out to remove the needle from the injection site.
Po 10 sekundah izvlecite napolnjen injekcijski peresnik
After 10 seconds, keep the dose setting knob pressed down, and take the needle out of your skin.
Po 10 sekundah izvlecite iglo iz kože in še vedno držite pritisnjen gumb za nastavitev odmerka.
After 10 years of follow-up in GEICAM 9805 study, , acute leukaemia occurred in 1 of 532 (0.2%) patients in TAC arm .
Po 10 letih spremljanja v študiji GEICAM 9805 se je akutna levkemija pojavila pri 1 od 532 (0,2 %) bolnic v kraku TAC.
After 10 years of follow-up in GEICAM 9805 study, , acute leukaemia occurred in 1 of 532 (0.2%) patients in TAC arm.
Po 10 letih spremljanja v študiji GEICAM 9805 se je akutna levkemija pojavila pri 1 od 532 (0,2 %) bolnic v kraku TAC.
After 10 years of follow-up in GEICAM 9805 study, acute leukaemia occurred in 1 of 532 (0.2%) patients in TAC arm.
Po 10 letih spremljanja v študiji GEICAM 9805 se je akutna levkemija pojavila pri 1 od 532 (0,2 %) bolnic v kraku TAC.
After 10 years of follow-up in GEICAM 9805 study, acute leukaemia occurred in 1 of 532 (0.2%) patients. in TAC arm.
Po 10 letih spremljanja v študiji GEICAM 9805 se je akutna levkemija pojavila pri 1 od 532 (0,2 %) bolnic v kraku TAC.
After 10 years of follow-up in GEICAM 9805 study,, acute leukaemia occurred in 1 of 532 (0.2%) patients in TAC arm .
Po 10 letih spremljanja v študiji GEICAM 9805 se je akutna levkemija pojavila pri 1 od 532 (0,2 %) bolnic v kraku TAC.
After 10 years, the marketing authorisation was renewed for a further five years.
Po desetih letih je bilo dovoljenje za promet podaljšano za nadaljnjih pet let.
After 12 months of treatment with bimatoprost eye drops alone, the incidence was 1.5% and did not increase following 3 years of treatment.
Po 12 mesecih zdravljenja s kapljicami za oko, ki so vsebovale samo bimatoprost, je bila incidenca 1,5 % in se v naslednjih 3 letih zdravljenja ni povečala.
After 12 months of treatment with GANFORT (multi-dose formulation), the incidence of iris pigmentation was 0.2%.
Po 12 mesecih zdravljenja z zdravilom GANFORT (večodmerna oblika) je bila incidenca pigmentacije šarenice 0,2 %.
After 12 months, BMD had increased in the lumbar spine and total hip by 5 % and 1 %, respectively, compared with placebo.
Po 12 mesecih se je mineralna gostota kosti (BMD) v ledvenem delu hrbtenice oziroma celem kolku povišala za 5 % oziroma 1 % v primerjavi s placebom.
After 12 to 18 months of maintenance therapy, Replagal improved renal function as measured by inulin based glomerular filtration rate by 8.7 ± 3.7 ml/min. (p=0.030).
Po 12 do 18 mesecih vzdrževalnega zdravljenja je zdravilo Replagal izboljšalo delovanje ledvic, merjeno s stopnjo glomerulne filtracije, temelječe na inulinu, za 8,7 ± 3,7 ml/min (p = 0,030).
After 12 to 18 months treatment a reduction of 50 – 80% was observed in plasma and urine sediment.
Po 12 do 18 mesecih zdravljenja so opazili za 50 do 80% zmanjšanje kopičenja Gb3 v plazmi in sedimentu seča.
After 12 weeks of therapy, patients who had received Humira in Period A were re-randomised in Period B to 1 of 3 treatment groups (Humira 40 mg every week, Humira 40 mg every other week, or placebo from Week 12 to Week 35).
Po 12. tednih terapije so bolnike, ki so prejemali zdravilo Humira v obdobju A, ponovno randomizirali v obdobju B v eno izmed treh skupin zdravljenja (zdravilo Humira 40 mg vsak teden, zdravilo Humira 40 mg vsak drugi teden ali placebo od 12. do 35. tedna).
After 12 weeks or at the time of switching to tocilizumab, due to disease worsening, patients were treated in the ongoing open label extension phase.
Po 12. tednih ali ob prehodu na tocilizumab zaradi poslabšanja bolezni so bolnike zdravili v odprti, podaljšani fazi, ki še poteka.
After 12 weeks, patients treated with Adempas could walk 36 metres further in six minutes than patients taking placebo.
Po 12 tednih so lahko bolniki, ki so jih zdravili z zdravilom Adempas, v šestih minutah prehodili 36 metrov več kot bolniki, ki so jemali placebo.
After 12 weeks, the viral load had fallen by more than 95%.
Po 12 tednih je virusna obremenitev upadla za več kot 95 %.
After 15 minutes, check that the medicine is not cloudy and does not have any bits in it.
Po 15 minutah preglejte zdravilo, da ni motno in da ne vsebuje delcev.